Measurement of serum Interleukin 34 (IL34) and correlation with severity and pruritus scores in client owned dogs with atopic dermatitis.

Deborah Gow, Hilary Jackson, Peter Forsythe, Tim Nuttall, Adam Gow, Richard Mellanby, David Hume

Research output: Contribution to journalArticlepeer-review

Abstract

Background – Atopic dermatitis (AD) is a common inflammatory skin disease of dogs. Interleukin 34 (IL34) is a monocyte/macrophage growth factor, produced mainly by keratinocytes, that has been implicated in several human inflammatory conditions including human AD.
Hypothesis – Canine serum IL34 concentrations are increased in dogs with AD and correlate with clinical lesion and pruritus scores.
Animals – 47 client owned dogs diagnosed with AD and 25 healthy, unaffected control dogs.
Methods – A commercially available IL34 ELISA was optimised for the measurement of IL34 in canine serum samples. Information regarding treatment, clinical lesion scores (CADESI-4) and pruritus (pVAS) were recorded for each dog at the time of serum collection.
Results – Dogs with AD had significantly increased serum IL34 concentrations compared to controls. There was a significant positive correlation between IL34 concentrations and CADESI-4 and pVAS scores. Concentrations of IL34 remained increased in dogs with AD receiving steroids or the JAK1 inhibitor, oclacitinib, compared to unaffected control dogs.
Conclusions and clinical importance – Serum IL34 concentrations are increased in dogs with AD and are correlated with clinical severity and pruritus. IL34 may be a suitable candidate therapeutic target for canine AD
Original languageEnglish
Pages (from-to)359-e94
JournalVeterinary Dermatology
Volume31
Early online date13 Aug 2020
DOIs
Publication statusPublished - 29 Sep 2020

Fingerprint

Dive into the research topics of 'Measurement of serum Interleukin 34 (IL34) and correlation with severity and pruritus scores in client owned dogs with atopic dermatitis.'. Together they form a unique fingerprint.

Cite this